Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Inks $4.35bn Nationwide US Opioids Settlement Agreement

US-Wide Documentation To Be Finalized ‘Within The Coming Weeks’

Executive Summary

Teva is to put more than $3bn in cash on the table over the next 13 years to resolve longstanding opioid-related claims against the company in the US.

You may also be interested in...



Teva Agrees $931,000 For Arkansas To Dismiss Price-Fixing Claims

Teva will pay $931, 000 to dismiss price-fixing claims filed in a 2020 multistate lawsuit but its legal troubles are far from over.  

Teva Reaches ‘Modest’ Settlement With Georgia Over Price-Fixing Allegations

Teva has made its third settlement with a US state following the Department of Justice’s price-fixing investigation, agreeing to pay Georgia $3.34m in exchange for the dismissal of all claims against the company and its affiliates.

The Generics Bulletin Top 50, Part One: Industry Top 10 Reshaped By Leaders’ Transformations

A new entrant into the top five global generics and biosimilars companies shows how transformations for some of the leading off-patent players are reshaping the industry landscape, with more major changes in the pipeline. We examine the 10 leaders of the pack in the first instalment of this year’s Generics Bulletin Top 50.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB152049

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel